Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
Rahmad MulyadiIrsan HasanPrijo SidipratomoPungky Permata PutriPublished in: Journal of the Egyptian National Cancer Institute (2024)
The results of this systematic review suggested that TACE-sorafenib combination therapy in patients with HCC BCLC-C improves OS superior compared to TACE-alone, without a notable increase in adverse events.